作者:Kalra, S.
关键词:Blood pressure; Cardiovascular diseases; Sodium-glucose cotransporter 2 (SGLT2) inhibitors; Treatment.
发表时间:2016
发表期刊:Cardiol Ther .
证据类型:系统评价/Meta分析
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of drugs that have been extensively investigated for the treatment of hyperglycemia in type 2 diabetes mellitus (T2DM). These drugs reduce hyperglycemia by blocking renal glucose reabsorption, thereby promoting increased renal glucose excretion. Beyond glycemic control, these drugs have other beneficial effects on cardiovascular (CV) risk factors. The present review discusses the potential role of SGLT2 inhibitors in treating CV complications (acute and chronic) associated with T2DM. FUNDING: AstraZeneca Pharma India Ltd.